Biomarin Pharmaceutical (MIL:1BMRN) Buildings And Improvements : €0 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Biomarin Pharmaceutical Buildings And Improvements?

Biomarin Pharmaceutical's quarterly buildings and improvements increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€789 Mil) but then declined from Dec. 2023 (€789 Mil) to Mar. 2024 (€0 Mil).

Biomarin Pharmaceutical's annual buildings and improvements increased from Dec. 2021 (€686 Mil) to Dec. 2022 (€773 Mil) and increased from Dec. 2022 (€773 Mil) to Dec. 2023 (€789 Mil).

Biomarin Pharmaceutical Buildings And Improvements Historical Data

The historical data trend for Biomarin Pharmaceutical's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Buildings And Improvements Chart

Biomarin Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Buildings And Improvements

Get a 7-Day Free Trial

653.32

626.00

685.81

773.23

789.36

Biomarin Pharmaceutical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Buildings And Improvements	Get a 7-Day Free Trial															-	-	-	789.36	-

Biomarin Pharmaceutical Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction. Broker and architect fees, permits, etc. can be covered within this category. Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized. Improvements are commonly recorded at acquisition cost. Building improvement examples include roofing, remodeling, replacements, etc.

Biomarin Pharmaceutical (MIL:1BMRN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (MIL:1BMRN) » Definitions » Buildings And Improvements

Comparable Companies

Traded in Other Exchanges

BMRN:USA BM8:Germany B1MR34:Brazil

Address

770 Lindaro Street, San Rafael, CA, USA, 94901

Website

http://www.bmrn.com

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (MIL:1BMRN) Headlines

No Headlines